Costimulation, a surprising connection for immunotherapy
- PMID: 28360282
- DOI: 10.1126/science.aan1467
Costimulation, a surprising connection for immunotherapy
Comment on
-
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.Science. 2017 Mar 31;355(6332):1428-1433. doi: 10.1126/science.aaf1292. Epub 2017 Mar 9. Science. 2017. PMID: 28280247 Free PMC article.
-
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.Science. 2017 Mar 31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9. Science. 2017. PMID: 28280249 Free PMC article.
Similar articles
-
Costimulation Engages the Gear in Driving CARs.Immunity. 2016 Feb 16;44(2):214-6. doi: 10.1016/j.immuni.2016.02.001. Immunity. 2016. PMID: 26885852
-
The Bumpy Road to CAR Activation.Mol Ther. 2019 Jan 2;27(1):14-16. doi: 10.1016/j.ymthe.2018.12.003. Epub 2018 Dec 13. Mol Ther. 2019. PMID: 30553566 Free PMC article. No abstract available.
-
Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses.Eur J Immunol. 1998 Mar;28(3):881-90. doi: 10.1002/(SICI)1521-4141(199803)28:03<881::AID-IMMU881>3.0.CO;2-0. Eur J Immunol. 1998. PMID: 9541583
-
Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy.Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9. Arch Immunol Ther Exp (Warsz). 1999. PMID: 10604232 Review.
-
Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.Immunotherapy. 2017 Jan;9(1):71-82. doi: 10.2217/imt-2016-0097. Immunotherapy. 2017. PMID: 28000531 Free PMC article. Review.
Cited by
-
Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels.J Immunother Cancer. 2019 Feb 12;7(1):43. doi: 10.1186/s40425-019-0526-z. J Immunother Cancer. 2019. PMID: 30755279 Free PMC article.
-
Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation.Oncoimmunology. 2019 Aug 28;8(11):1652532. doi: 10.1080/2162402X.2019.1652532. eCollection 2019. Oncoimmunology. 2019. PMID: 31646081 Free PMC article.
-
The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment.Oncotarget. 2019 Jul 16;10(44):4532-4545. doi: 10.18632/oncotarget.27027. eCollection 2019 Jul 16. Oncotarget. 2019. PMID: 31360302 Free PMC article.
-
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.Immune Netw. 2022 Feb 14;22(1):e2. doi: 10.4110/in.2022.22.e2. eCollection 2022 Feb. Immune Netw. 2022. PMID: 35291660 Free PMC article. Review.
-
4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.Clin Cancer Res. 2020 Mar 15;26(6):1349-1358. doi: 10.1158/1078-0432.CCR-19-1068. Epub 2019 Dec 23. Clin Cancer Res. 2020. PMID: 31871298 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources